Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | BCL2 | P10415 | 1/20 | 0.40 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | SCD | O00767 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16310724 | 0.94 | NAMPT (0.45) | NAMPTHDAC1GRIN2BCYP17A1SCN9A | |
| SCHEMBL6058644 | 0.94 | NAMPT (0.45) | NAMPTHDAC1GRIN2BCYP17A1SCN9A | |
| SCHEMBL10087556 | 0.88 | NAMPT (0.49) | NAMPTHDAC1GRIN2BCYP17A1SCN9A | |
| SCHEMBL5076532 | 0.84 | NAMPT (0.47) | NAMPTHDAC1GRIN2BCYP17A1SCN9A | |
| SCHEMBL28031221 | 0.84 | NAMPT (0.43) | NAMPTHDAC1GRIN2BCYP17A1SCN9A | |
| SCHEMBL949620 | 0.84 | NAMPT (0.48) | NAMPTHDAC1GRIN2BCYP17A1SCN9A | |
| SCHEMBL15354526 | 0.83 | NAMPT (0.50) | NAMPTHDAC1GRIN2BCYP17A1SCN9A | |
| SCHEMBL540536 | 0.83 | NAMPT (0.50) | NAMPTHDAC1GRIN2BCYP17A1SCN9A | |
| SCHEMBL6058817 | 0.83 | NAMPT (0.43) | NAMPTHDAC1GRIN2BCYP17A1SCN9A | |
| SCHEMBL16296336 | 0.83 | NAMPT (0.43) | NAMPTHDAC1GRIN2BCYP17A1SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834527-B2 | Macrocyclic urea derivatives as inhibitors of TAFIa, their preparation and their use as pharmaceuticals | SANOFI (FR) | 2017-12-05 | — | — | US | disclosed |
| EP-3027611-B1 | MACROCYCLIC UREA DERIVATIVES AS INHIBITORS OF TAFI A, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2017-07-26 | — | — | EP | disclosed |
| EP-3027611-A1 | MACROCYCLIC UREA DERIVATIVES AS INHIBITORS OF TAFI A, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2016-06-08 | — | — | EP | disclosed |
| US-20160137618-A1 | Macrocyclic Urea Derivatives as Inhibitors of TAFIa, Their Preparation and Their Use as Pharmaceuticals | SANOFI (FR) | 2016-05-19 | — | — | US | disclosed |
| WO-2014198620-A1 | MACROCYCLIC UREA DERIVATIVES AS INHIBITORS OF TAFIA, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137618-A1 | Macrocyclic Urea Derivatives as Inhibitors of TAFIa, Their Preparation and Their Use as Pharmaceuticals | TFPI, TFPI2, F12 | NAMPT 2411/4885HDAC1 852/4885GRIN2B 4738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.